drugset / Trial / NCT04542135
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer
Phase 2
Completed
61 enrolled
Alison Stopeck
Cedars-Sinai Medical Center · collabMedical University of South Carolina · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
The primary objective of this study is to determine if sulindac at a dose of 150 mg twice a day for 12 months reduces breast density in postmenopausal women at elevated risk of breast cancer when compared to a placebo control.
Timeline
- Start
- 2020-11-20
- Primary completion
- 2025-04-22
- Completion
- 2025-05-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Sulindac | Small molecule | 150 mg | Oral |